Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cingulate Inc. stock logo
CING
Cingulate
$5.10
-1.5%
$4.52
$1.80
$20.83
$26.66M-0.79116,028 shs64,133 shs
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
$6.09
+2.4%
$5.86
$4.65
$10.24
$99.51M0.2683,647 shs39,841 shs
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$1.62
-6.9%
$1.64
$1.02
$6.81
$98.47M0.99313,221 shs462,376 shs
Zura Bio Limited stock logo
ZURA
Zura Bio
$1.50
+7.1%
$1.28
$0.97
$5.07
$95.72M-0.06966,579 shs471,118 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cingulate Inc. stock logo
CING
Cingulate
-1.54%-7.27%+17.51%+18.06%+1,344.35%
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
+2.35%-8.70%+5.36%-4.40%-11.22%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-6.90%-16.06%+10.20%+1.25%-77.31%
Zura Bio Limited stock logo
ZURA
Zura Bio
+7.14%-8.54%+33.93%+2.04%-62.03%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cingulate Inc. stock logo
CING
Cingulate
3.207 of 5 stars
3.55.00.00.03.20.80.6
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
1.957 of 5 stars
3.53.00.00.01.90.80.0
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3.1587 of 5 stars
3.55.00.00.00.63.30.6
Zura Bio Limited stock logo
ZURA
Zura Bio
3.6303 of 5 stars
3.65.00.00.03.42.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cingulate Inc. stock logo
CING
Cingulate
3.00
Buy$26.00409.80% Upside
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
3.00
Buy$16.50170.94% Upside
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3.00
Buy$7.80381.48% Upside
Zura Bio Limited stock logo
ZURA
Zura Bio
3.13
Buy$14.33855.56% Upside

Current Analyst Ratings Breakdown

Latest CING, ZURA, COYA, and TCRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/24/2025
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
7/9/2025
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$16.00
7/1/2025
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
6/9/2025
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
5/27/2025
Cingulate Inc. stock logo
CING
Cingulate
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$60.00 ➝ $61.00
5/19/2025
Cingulate Inc. stock logo
CING
Cingulate
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$12.00 ➝ $11.00
5/13/2025
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
5/9/2025
Zura Bio Limited stock logo
ZURA
Zura Bio
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$19.00 ➝ $17.00
5/7/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $10.00
5/6/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$7.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cingulate Inc. stock logo
CING
Cingulate
N/AN/AN/AN/A$2.32 per shareN/A
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
$3.69M27.64N/AN/A$2.37 per share2.57
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$2.82M32.51N/AN/A$4.26 per share0.38
Zura Bio Limited stock logo
ZURA
Zura Bio
N/AN/AN/AN/A$2.27 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cingulate Inc. stock logo
CING
Cingulate
-$15.55M-$8.48N/AN/AN/AN/A-229.78%-142.28%8/12/2025 (Estimated)
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
-$14.88M-$1.07N/AN/AN/AN/A-48.88%-43.32%8/11/2025 (Estimated)
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$127.50M-$1.09N/AN/AN/A-2,974.08%-55.76%-36.56%8/11/2025 (Estimated)
Zura Bio Limited stock logo
ZURA
Zura Bio
-$45.39M-$0.70N/AN/AN/AN/A-42.84%-35.22%8/12/2025 (Estimated)

Latest CING, ZURA, COYA, and TCRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Cingulate Inc. stock logo
CING
Cingulate
-$0.82N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Zura Bio Limited stock logo
ZURA
Zura Bio
-$0.19N/AN/AN/AN/AN/A
8/11/2025Q2 2025
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
-$0.22N/AN/AN/AN/AN/A
8/11/2025Q2 2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.28N/AN/AN/A$1.31 millionN/A
5/13/2025Q1 2025
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
-$0.44-$0.44N/A-$0.44$2.63 million$257.88 million
5/12/2025Q1 2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.28-$0.26+$0.02-$0.26$1.62 million$2.17 million
5/8/2025Q1 2025
Cingulate Inc. stock logo
CING
Cingulate
-$1.00-$1.04-$0.04-$1.04N/AN/A
5/8/2025Q1 2025
Zura Bio Limited stock logo
ZURA
Zura Bio
-$0.17-$0.19-$0.02-$0.19N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cingulate Inc. stock logo
CING
Cingulate
N/AN/AN/AN/AN/A
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
N/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
N/AN/AN/AN/AN/A
Zura Bio Limited stock logo
ZURA
Zura Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cingulate Inc. stock logo
CING
Cingulate
0.16
1.87
1.87
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
N/A
8.84
8.84
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.15
8.55
8.55
Zura Bio Limited stock logo
ZURA
Zura Bio
N/A
8.14
8.14

Institutional Ownership

CompanyInstitutional Ownership
Cingulate Inc. stock logo
CING
Cingulate
41.31%
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
39.75%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
82.83%
Zura Bio Limited stock logo
ZURA
Zura Bio
61.14%

Insider Ownership

CompanyInsider Ownership
Cingulate Inc. stock logo
CING
Cingulate
5.27%
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
12.00%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
4.35%
Zura Bio Limited stock logo
ZURA
Zura Bio
14.23%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cingulate Inc. stock logo
CING
Cingulate
205.15 million4.88 millionNot Optionable
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
616.73 million14.72 millionNot Optionable
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
10056.59 million54.13 millionNot Optionable
Zura Bio Limited stock logo
ZURA
Zura Bio
368.38 million58.65 millionOptionable

Recent News About These Companies

Zura Bio price target lowered to $3 from $5 at H.C. Wainwright
Zura Bio (ZURA) Gets a Buy from Guggenheim

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cingulate stock logo

Cingulate NASDAQ:CING

$5.10 -0.08 (-1.54%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$4.69 -0.41 (-8.12%)
As of 08/1/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Coya Therapeutics stock logo

Coya Therapeutics NASDAQ:COYA

$6.09 +0.14 (+2.35%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$6.06 -0.04 (-0.57%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

TScan Therapeutics stock logo

TScan Therapeutics NASDAQ:TCRX

$1.62 -0.12 (-6.90%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.58 -0.05 (-2.78%)
As of 08/1/2025 06:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Zura Bio stock logo

Zura Bio NASDAQ:ZURA

$1.50 +0.10 (+7.14%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.50 0.00 (0.00%)
As of 08/1/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.